Citation Impact
Citing Papers
KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD)
2009 Standout
Vertebral Fractures After Discontinuation of Denosumab: A Post Hoc Analysis of the Randomized Placebo-Controlled FREEDOM Trial and Its Extension
2017
Managing Osteoporosis in Patients on Long-Term Bisphosphonate Treatment: Report of a Task Force of the American Society for Bone and Mineral Research
2015
European guidance for the diagnosis and management of osteoporosis in postmenopausal women
2012 Standout
Wnt/β-catenin signalling: function, biological mechanisms, and therapeutic opportunities
2022 Standout
Bone grafts and biomaterials substitutes for bone defect repair: A review
2017 Standout
Clinician’s Guide to Prevention and Treatment of Osteoporosis
2014 Standout
Bone regeneration: current concepts and future directions
2011 Standout
American Association of Clinical Endocrinologists and American College of Endocrinology Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis — 2016--Executive Summary
2016
Bisphosphonate-related osteonecrosis of the jaws – A review
2012
Child abuse: Adolescent records vs. adult recall
1990 Standout
Health benefits of physical activity: the evidence
2006 Standout
Fracture healing: mechanisms and interventions
2014 Standout
2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary
2010
Osteoporosis
2019 Standout
Oxidative stress, aging, and diseases
2018 Standout
The effects of Dickkopf-1 antibody on metaphyseal bone and implant fixation under different loading conditions
2011
Frailty and sarcopenia as the basis for the phenotypic manifestation of chronic diseases in older adults
2016
Nrf2-Keap1 signaling in oxidative and reductive stress
2018 Standout
Parathyroid Hormone and Bone Healing
2010
The control of fracture healing and its therapeutic targeting: Improving upon nature
2009
Updated recommendations for managing the care of patients receiving oral bisphosphonate therapy
2008
Treatment of Low Bone Density or Osteoporosis to Prevent Fractures in Men and Women: A Clinical Practice Guideline Update From the American College of Physicians
2017
Effects of abaloparatide-SC (BA058) on bone histology and histomorphometry: The ACTIVE phase 3 trial
2016
Endogenous tissue engineering: PTH therapy for skeletal repair
2011
Osteoporosis: now and the future
2011 Standout
3D bioactive composite scaffolds for bone tissue engineering
2017 Standout
WNT signaling in bone homeostasis and disease: from human mutations to treatments
2013 Standout
Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards
2010
Epidemiology and pathogenesis of osteonecrosis of the jaw
2011
Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial
2017
Recommendations and Considerations for the Use of Biologics in Orthopedic Surgery
2012
Adverse Reactions and Drug–Drug Interactions in the Management of Women with Postmenopausal Osteoporosis
2011
Bone Tissue Engineering: Recent Advances and Challenges
2012 Standout
Correlation Between Serum C-Terminal Cross-Linking Telopeptide of Type I Collagen and Staging of Oral Bisphosphonate-Related Osteonecrosis of the Jaws
2009
Using Osteoporosis Therapies in Combination
2017
Sarcopenia
2019 Standout
Parathyroid Hormone 1-84 Accelerates Fracture-Healing in Pubic Bones of Elderly Osteoporotic Women
2011
Effects of Teriparatide Compared with Risedronate on Recovery After Pertrochanteric Hip Fracture
2016
Néstor–Guillermo progeria syndrome: A novel premature aging condition with early onset and chronic development caused by BANF1 mutations
2011
Managing the care of patients receiving antiresorptive therapy for prevention and treatment of osteoporosis
2011
Management of severe osteoporosis
2015
The Incidence of Osteonecrosis of the Jaw in Patients Receiving 5 Milligrams of Zoledronic Acid
2010
Emerging therapeutic concepts for muscle and bone preservation/building
2015
Teriparatide improves early callus formation in distal radial fractures
2010
The Hallmarks of Aging
2013 Standout
Use of Teriparatide to improve fracture healing: What is the evidence?
2015
10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension
2017
Clinical advantages and disadvantages of anabolic bone therapies targeting the WNT pathway
2018
Teriparatide and Osseous Regeneration in the Oral Cavity
2010
Annotation: Parathyroid hormone and fracture healing
2013
Inflammatory bone loss: pathogenesis and therapeutic intervention
2012 Standout
Cell Sources for Bone Tissue Engineering: Insights from Basic Science
2011
American Association of Clinical Endocrinologists and American College of Endocrinology Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis — 2016
2016
Skeletal muscle aging: influence of oxidative stress and physical exercise
2017
Sclerostin antibody treatment enhances metaphyseal bone healing in rats
2010
Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis (TRIPOD): Explanation and Elaboration
2015 Standout
Capturing Magnesium Ions via Microfluidic Hydrogel Microspheres for Promoting Cancellous Bone Regeneration
2021 Standout
2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines
2019 Standout
Standardized nomenclature, symbols, and units for bone histomorphometry: A 2012 update of the report of the ASBMR Histomorphometry Nomenclature Committee
2012 Standout
Recommendations and Considerations for the Use of Biologics in Orthopedic Surgery
2012
Inhibition of sclerostin by monoclonal antibody enhances bone healing and improves bone density and strength of nonfractured bones
2010
Systematic Review: Comparative Effectiveness of Treatments to Prevent Fractures in Men and Women with Low Bone Density or Osteoporosis
2008
Bone Grafts and Substitutes in Dentistry: A Review of Current Trends and Developments
2021 Standout
Goal-Directed Treatment for Osteoporosis: A Progress Report From the ASBMR-NOF Working Group on Goal-Directed Treatment for Osteoporosis
2016
The effect of 3 versus 6 years of Zoledronic acid treatment of osteoporosis: A randomized extension to the HORIZON-Pivotal Fracture Trial (PFT)
2011
Addressing unmeasured confounding in comparative observational research
2018 StandoutNobel
Longitudinal Effects of Teriparatide or Zoledronic Acid on Bone Modeling- and Remodeling-Based Formation in the SHOTZ Study
2017
American Association of Oral and Maxillofacial Surgeons Position Paper on Medication-Related Osteonecrosis of the Jaw—2014 Update
2014 Standout
FEA to Measure Bone Strength: A Review
2016
Works of Christopher Recknor being referenced
Effects of Teriparatide in Postmenopausal Women with Osteoporosis on Prior Alendronate or Raloxifene: Differences between Stopping and Continuing the Antiresorptive Agent
2009
Impact of denosumab on the peripheral skeleton of postmenopausal women with osteoporosis
2012
Skeletal Histomorphometry in Subjects on Teriparatide or Zoledronic Acid Therapy (SHOTZ) Study: A Randomized Controlled Trial
2012
Comparison of proximal femur and vertebral body strength improvements in the FREEDOM trial using an alternative finite element methodology
2015
Myostatin antibody (LY2495655) in older weak fallers: a proof-of-concept, randomised, phase 2 trial
2015
The effect of teriparatide compared with risedronate on reduction of back pain in postmenopausal women with osteoporotic vertebral fractures
2011
Efficacy and tolerability of once-monthly oral ibandronate (150 mg) and once-weekly oral alendronate (70 mg): Additional results from the monthly oral therapy with ibandronate for osteoporosis intervention (MOTION) study
2009
Denosumab significantly increases bone mineral density and reduces bone turnover compared with monthly oral ibandronate and risedronate in postmenopausal women who remained at higher risk for fracture despite previous suboptimal treatment with an oral bisphosphonate
2014
Comparative effects of raloxifene and alendronate on fracture outcomes in postmenopausal women with low bone mass
2006
Incidence of Osteonecrosis of the Jaw in Women With Postmenopausal Osteoporosis in the Health Outcomes and Reduced Incidence With Zoledronic Acid Once Yearly Pivotal Fracture Trial
2008
Differential Effects of Teriparatide and Denosumab on Intact PTH and Bone Formation Indices: AVA Osteoporosis Study
2016
A Longitudinal Study of Skeletal Histomorphometry at 6 and 24 Months Across Four Bone Envelopes in Postmenopausal Women With Osteoporosis Receiving Teriparatide or Zoledronic Acid in the SHOTZ Trial
2016
The Effect of Discontinuing Treatment With Blosozumab: Follow-up Results of a Phase 2 Randomized Clinical Trial in Postmenopausal Women With Low Bone Mineral Density
2015
Discontinuation of denosumab and associated fracture incidence: Analysis from the Fracture Reduction Evaluation of Denosumab in Osteoporosis Every 6 Months (FREEDOM) Trial
2012
Teriparatide for acceleration of fracture repair in humans: A prospective, randomized, double-blind study of 102 postmenopausal women with distal radial fractures
2009
Remodeling- and Modeling-Based Bone Formation With Teriparatide Versus Denosumab: A Longitudinal Analysis From Baseline to 3 Months in the AVA Study
2017